American Society of Clinical Oncology 2020 annual meeting
Oncologica presents data relating to the performance of the Oncofocus test and the identification of new treatment options for patients with advanced cancers “The actionable genomic mutational landscape in solid tumours”.
Advances in somatic cancer genetics and genomic profiling has led to the development of targeted drugs and immunotherapies that are directed against the cancer genes that cause malignancy. These new anti-cancer agents, which specifically target cancer cells, are associated with much higher response rates when compared with conventional chemotherapy. Moreover targeted agents and immunotherapies specifically directed at cancer cells leave normal cells undisturbed and therefore have much fewer side effects. In contrast chemotherapy stops normal cell dividing leading to serious side effects such as hair loss, nausea, anaemia and infections.
In routine clinical practice cancer gene testing for targeted treatments is restricted to a small number genes applied to only a few cancer types e.g. EGFR, ALK, ROS, PD-L1 and TRK in lung cancer, HER2 in breast cancer, BRAF in melanoma and RAS and RAF in bowel cancer. However these mutations are linked to only a handful of targeted agents and immunotherapies. Importantly over 750 targeted agents and immunotherapies have now been developed against hundreds of cancer genes and these mutated genes are found across all tumour types such as glioblastoma, pancreatic, prostate, kidney, ovarian, lung and lymphoma. However these treatment options remain undiscovered for many cancer patients because tumours are not routinely tested for these cancer genes.
To address this unmet clinical need Oncologica has developed the Oncofocus test which can be applied to all tumour types enabling all modern targeted anti-cancer agents and immunotherapies specific to a patient’s individual tumour to be identified. Here we present exciting data at the ASCO conference showing that Oncofocus precision oncology testing is able to identify personalised treatment options in >90% of patients with advanced cancer providing potential linkage with over 750 modern anti-cancer agents.